Supplementary MaterialsSupplementary material 1 (DOCX 1010 kb) 40744_2019_164_MOESM1_ESM. Edoxaban tosylate *C-reactive protein, functional assessment of chronic illness therapy-fatigue, swollen joint count-28, tender joint count-28, visual analog level Treatment Effect upon Pain, Fatigue, and WPAI-RA at Weeks 12 and 24 At week 12, patients treated with baricitinib and adalimumab reported statistically significantly greater improvements from baseline for both pain and fatigue compared with placebo-treated patients ( em p? /em ?0.001) [6] (Table?2). For pain, the change from baseline was greater for baricitinib-treated compared with adalimumab-treated patients ( em p? /em ?0.01). Similarly, at week 12, patients treated with baricitinib or adalimumab reported improvements in their daily activity. Baricitinib-treated patients reported improvement in work productivity compared with placebo; in contrast, there were no statistically significant differences for adalimumab compared with placebo (Table?2). Similar styles were observed at week 24 (Table?2). Association of Pain and Fatigue with Daily Activity and Work Productivity For all those patients combined at week 12, patients with??50% reduction in pain from baseline had significantly greater improvements ( em p? /em ?0.001) in daily activity and work productivity compared to those with less reduction in pain (Fig.?1). At week 24, patients with??50% reduction in pain from baseline reported statistically significant improvements ( em p? /em ?0.001) only in daily activity compared to those with less pain reduction. Similar findings were observed for baricitinib-treated patients at weeks 12 and 24 (Physique S3). Open in a separate window Fig.?1 a The relationship of pain and fatigue with improvement in daily activity at weeks 12 and 24. * em p /em ??0.05, ** em p /em ??0.01, *** em p /em ??0.001 vs.? ?30% pain reduction; ? em p /em ??0.05, ?? em p /em ??0.01, ??? em p /em ??0.001 vs. 30 to ?50% pain reduction. b The relationship of pain and fatigue with improvement in work productivity at weeks 12 and 24. * em p /em ??0.05, ** em p /em ??0.01, *** em p /em ??0.001 vs.? ?30% pain reduction; ? em p /em ??0.05, ?? em p /em ??0.01, ??? em p /em ??0.001 Edoxaban tosylate vs. 30 to ?50% pain reduction At weeks 12 and 24, patients who experienced a clinically relevant change in fatigue, a FACIT-F MCID of??3.56 from baseline, also experienced significantly greater improvements in daily activity and work productivity compared to those who did not accomplish the MCID (Fig.?1). Comparable results were observed among baricitinib-treated patients (Fig.?1, Physique S5). At weeks 12 and 24, those patients who reported values that met or exceeded the normal value of fatigue (FACIT-F??40.1) and the lowest levels of remaining pain (pain VAS??10?mm), reported approximately 30% improvement in daily activities (Fig.?2). For each increasing level of remaining pain, improvement in daily activity decreased. Additionally, patients with less fatigue tended to statement greater improvement in daily activity compared to those who reported more fatigue. Open in a separate windows Fig.?2 a Pain, fatigue, and improvement in daily activity at week 12. b Pain, fatigue, and improvement in daily activity at week 24. c Pain, fatigue, and improvement in work productivity at week 12. d Pain, fatigue, and improvement in work productivity at week 24 At the lowest levels of remaining pain (?10?mm), fatigue did not appear to affect work productivity. For example, at week 12, among patients with minimal remaining pain (?10?mm), the percentage of improvement in work productivity was 26% and 31% for those with low (?40.1) and higher ( ?40.1) levels of fatigue, respectively. With increasing levels of pain ( ?10?mm), levels of fatigue tended to have a greater relationship with work productivity improvement (Fig.?2, Physique S5). Mediator Analysis The total effect of baricitinib over placebo on daily activity or work productivity tended to be greater than that for adalimumab over placebo at both weeks 12 and 24 (Fig.?3). In the mediation analysis, the contributions of pain, fatigue, and disease activity by treatment on daily activity or work productivity represented the combined indirect effect or the mediation effect while the total treatment effect on daily activity Edoxaban tosylate or work productivity that is not accounted for by the mediation effect is called direct effect. The mediation effect accounted for the majority of the total effect (indirect and direct effect combined) in improvements in daily activity Rabbit Polyclonal to IFI6 or work productivity over placebo at weeks 12 or 24 (Fig.?3). Open in a separate windows Fig.?3 Mediator analysis to assess the contribution of pain, fatigue, and disease activity Edoxaban tosylate on daily activity and work productivity by treatment at weeks 12 and 24 Conversation The burden of RA for patients in this trial was high in terms of baseline impairments in daily activity and work productivity. Specifically, across all patients at baseline, the daily activity impairment was? ?50%. Of the 545 patients who were employed at baseline, the work productivity impairment ranged from 45 to 49%. Treatment with baricitinib or adalimumab resulted in reductions of pain and fatigue and improvements in daily activity and work productivity compared to placebo. In our analyses, we observed that pain and fatigue tended to be more correlated with daily activity and work productivity, compared to other measures, such as CRP, TJC, and SJC, thus confirming the feasibility of focusing on pain and fatigue as factors for impairments in daily activity.